Kayıkçı, ÖmürMehtap, Ö.Sarı, İ.Demirkan, F.Beyan, C.Çetin, G.Tekgündüz, E.Akpınar, Seval2023-04-202023-04-2020221300-7777https://doi.org/10.4274/tjh.galenos.2022.2022.0052https://hdl.handle.net/20.500.11776/11069Objective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event-free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy. © 2022 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.en10.4274/tjh.galenos.2022.2022.0052info:eu-repo/semantics/openAccessAutologous stem cell transplantationLymphomasNon-Hodgkin lymphomaT-cell lymphomasanaplastic lymphoma kinasefluorodeoxyglucose f 18antineoplastic agentabdomenadultanaplastic large cell lymphomaArticleautologous hematopoietic stem cell transplantationautologous stem cell transplantationbiopsybone marrow biopsycancer patientcancer prognosiscancer survivalcomputer assisted tomographyfemalehematopoietic cellhumanhuman tissueInternational Prognostic Indexliver function testlymph nodemalemulticenter studyneckNon Cutaneous Peripheral T Cell Lymphomanonhodgkin lymphomaoverall response rateoverall survivalpelvisperipheral T cell lymphomaphysical examinationpositron emission tomographyprogression free survivalremissionretrospective studyrisk factorsalvage therapythoraxtransplantationtreatment outcomeautotransplantationclinical trialhematologyhematopoietic stem cell transplantationpathologyperipheral T cell lymphomaprocedurestreatment outcomeAntineoplastic Combined Chemotherapy ProtocolsHematologyHematopoietic Stem Cell TransplantationHumansLymphoma, T-Cell, PeripheralRetrospective StudiesTransplantation, AutologousTreatment OutcomeArticle393170177Q3WOS:0008834738000032-s2.0-85137000431112736335678126Q3